{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:37:49Z","timestamp":1759941469530},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The live, attenuated, tetravalent dengue vaccine (CYD-TDV) is licensed in a number of dengue endemic countries for individuals \u22659 years of age. Before the integration of any vaccine into childhood vaccination schedules, a lack of immune interference and acceptable safety when coadministered with other recommended vaccines should be demonstrated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This randomized, multi-center phase III trial was conducted in Mexico. Healthy toddlers (n = 732) received a booster dose of a licensed pentavalent combination vaccine [diphtheria, tetanus, acellular pertussis, inactivated polio vaccine and <jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic> type b (DTaP-IPV\/\/Hib)] either concomitantly or sequentially, with the second dose of CYD-TDV administered as a 3-dose schedule. Antibody titers against diphtheria toxoid, tetanus toxoid and pertussis antigens were measured by enzyme-linked immunosorbent assay. Antibodies against poliovirus and dengue serotypes were measured using a plaque reduction neutralization test. Noninferiority was demonstrated for each of the DTaP-IPV\/\/Hib antigens if the lower limit of the 2-sided 95% confidence interval of the difference in seroconversion rates between the 2 groups (CYD-TDV and placebo) was \u226510%. Safety of both vaccines was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Noninferiority in immune response was demonstrated for all DTaP-IPV\/\/Hib antigens. After 3 doses of CYD-TDV, no difference was observed in the immune response for CYD-TDV between groups. There were no safety concerns during the study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Coadministration of the DTaP-IPV\/\/Hib booster vaccine with CYD-TDV has no observed impact on the immunogenicity or safety profile of the DTaP-IPV\/\/Hib booster vaccine. No difference was observed on the CYD-TDV profile when administered concomitantly or sequentially with the DTaP-IPV\/\/Hib booster vaccine.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001542","type":"journal-article","created":{"date-parts":[[2017,1,7]],"date-time":"2017-01-07T22:19:10Z","timestamp":1483827550000},"page":"602-608","source":"Crossref","is-referenced-by-count":13,"title":["Immunogenicity and Safety of a Booster Injection of DTap-IPV\/\/Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15\u201318 Months of Age in Mexico"],"prefix":"10.1097","volume":"36","author":[{"given":"Flor Irene Rodriguez","family":"Melo","sequence":"first","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Juan Renteria","family":"Morales","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiel Homero Mascare\u00f1as","family":"De Los Santos","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Rivas","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Vigne","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Noriega","sequence":"additional","affiliation":[{"name":"Clinical Sciences, Sanofi Pasteur, Swiftwater, Pennsylvania."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMra1110265","article-title":"Dengue.","volume":"366","author":"Simmons","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue.","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America.","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease.","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R7-20230912","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1179\/2046904712Z.00000000046","article-title":"Dengue: an escalating public health problem in Latin America.","volume":"32","author":"Tapia-Conyer","year":"2012","journal-title":"Paediatr Int Child Health"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses.","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"962","DOI":"10.4269\/ajtmh.12-0461","article-title":"Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.","volume":"88","author":"Timiryasova","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diagmicrobio.2005.04.013","article-title":"Molecular detection and serotypic characterization of dengue viruses by single-tube multiplex reverse transcriptase-polymerase chain reaction.","volume":"52","author":"Kumaria","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R11-20230912","article-title":"Dengue.","year":"2009","journal-title":"Guidelines for diagnosis, treatment, prevention and control"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.trivac.2014.07.002","article-title":"Virological confirmation of suspected dengue in a phase 2 Latin American vaccine trial: implications for vaccine efficacy evaluation.","author":"Boaz","year":"2014;3","journal-title":"Trials in Vaccinology"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods.","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1586\/erv.11.72","article-title":"A DTaP-IPV\/\/PRP~T vaccine (Pentaxim): a review of 16 years\u2019 clinical experience.","volume":"10","author":"Plotkin","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"R16-20230912","first-page":"282","article-title":"Immunogenicity and safety of a DTaP-IPV\/\/PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.","volume":"40","author":"Thisyakorn","year":"2009","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1016\/j.vaccine.2012.07.043","article-title":"Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.","volume":"30","author":"Lanata","year":"2012","journal-title":"Vaccine"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/INF.0b013e3181fe05af","article-title":"Live-attenuated tetravalent dengue vaccine in dengue-na\u00efve children, adolescents, and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity.","volume":"30","author":"Poo","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/aje\/kws317","article-title":"Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study.","volume":"177","author":"Nelson","year":"2013","journal-title":"Am J Epidemiol"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/INF.0000000000001250","article-title":"Immunogenicity and safety of yellow fever vaccine (stamaril) when administered concomitantly with a tetravalent dengue vaccine candidate in healthy toddlers at 12-13 months of age in Colombia and Peru: a randomized trial.","volume":"35","author":"L\u00f3pez","year":"2016","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201706000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:07:17Z","timestamp":1694556437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201706000-00014"}},"subtitle":["A Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001542","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}